GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Astria Therapeutics Inc (NAS:ATXS) » Definitions » Cyclically Adjusted PB Ratio

Astria Therapeutics (Astria Therapeutics) Cyclically Adjusted PB Ratio : 0.21 (As of May. 15, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Astria Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-15), Astria Therapeutics's current share price is $9.71. Astria Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $47.11. Astria Therapeutics's Cyclically Adjusted PB Ratio for today is 0.21.

The historical rank and industry rank for Astria Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

ATXS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.43
Current: 0.21

During the past years, Astria Therapeutics's highest Cyclically Adjusted PB Ratio was 0.43. The lowest was 0.00. And the median was 0.00.

ATXS's Cyclically Adjusted PB Ratio is ranked better than
82.74% of 643 companies
in the Biotechnology industry
Industry Median: 1.78 vs ATXS: 0.21

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Astria Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was $4.961. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $47.11 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Astria Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Astria Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astria Therapeutics Cyclically Adjusted PB Ratio Chart

Astria Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.16

Astria Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.21 0.16 0.30

Competitive Comparison of Astria Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Astria Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astria Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Astria Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Astria Therapeutics's Cyclically Adjusted PB Ratio falls into.



Astria Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Astria Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=9.71/47.11
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astria Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Astria Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.961/129.4194*129.4194
=4.961

Current CPI (Mar. 2024) = 129.4194.

Astria Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -316.521 99.070 -413.486
201503 58.436 99.621 75.915
201506 265.093 100.684 340.751
201509 233.543 100.392 301.071
201512 197.841 99.792 256.577
201603 162.965 100.470 209.921
201606 128.000 101.688 162.907
201609 118.654 101.861 150.756
201612 92.740 101.863 117.829
201703 71.874 102.862 90.431
201706 57.513 103.349 72.021
201709 41.032 104.136 50.994
201712 29.922 104.011 37.231
201803 26.721 105.290 32.845
201806 38.693 106.317 47.101
201809 34.223 106.507 41.585
201812 29.355 105.998 35.841
201903 26.027 107.251 31.407
201906 22.517 108.070 26.965
201909 19.602 108.329 23.418
201912 17.237 108.420 20.576
202003 18.006 108.902 21.398
202006 16.212 108.767 19.290
202009 14.736 109.815 17.367
202012 12.149 109.897 14.307
202103 -25.916 111.754 -30.013
202106 2.895 114.631 3.268
202109 2.616 115.734 2.925
202112 1.991 117.630 2.191
202203 1.021 121.301 1.089
202206 0.232 125.017 0.240
202209 1.046 125.227 1.081
202212 4.539 125.222 4.691
202303 4.146 127.348 4.213
202306 3.749 128.729 3.769
202309 3.179 129.860 3.168
202312 3.602 129.419 3.602
202403 4.961 129.419 4.961

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Astria Therapeutics  (NAS:ATXS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Astria Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Astria Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Astria Therapeutics (Astria Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
75 State Street, Suite 1400, Boston, MA, USA, 02109
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
Executives
Perceptive Life Sciences Master Fund Ltd director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Andrea Matthews officer: Chief Business Officer C/O ASTRIA THERAPEUTICS, INC., 75 STATE STREET, SUITE 1400, BOSTON MA 02109
Christopher Morabito officer: Chief Medical Officer C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Andrew Komjathy officer: Chief Commercial Officer CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B14202, CAMBRIDGE MA 02139
Andrew John Nichols officer: Chief Scientific Officer C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG 1400E, CAMBRIDGE MA 02139
Perceptive Xontogeny Venture Fund, Lp director, 10 percent owner C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Jonathan Violin director 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Fred Callori director 100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Xontogeny, Llc director, 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc director, 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joanne T. Beck director C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ, BLD. 1400E, SUITE B14202, CAMBRIDGE MA 02139
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Hugh M Cole director C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Benjamin Harshbarger officer: Secretary and General Counsel ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142